Atlas Discovery vs Insitro
Insitro holds the stronger position because its years of proprietary data and signed pharma partnerships give it real protection that three-person, $500K-funded Atlas Discovery does not have.
Atlas Discovery
Pre-seed startup building AI foundation models to predict patient drug response
Insitro
AI drug discovery company using genomics and cell data to find new medicines
Dimension by dimension
| Dimension | Atlas Discovery | Insitro |
|---|---|---|
| Staying power of the core product | Atlas has no named customers and only 3 employees, so there is no track record showing its models hold up once used in real trials. | Insitro has multi-year partnerships with Lilly, Novartis and J&J that keep its platform in use even after recent layoffs. |
| Exposure to AI absorbing the product | Atlas's core idea, predicting trial responders, is rated likely to be folded into broader AI tools over time. | Insitro is only partly exposed, since its work leans on proprietary lab and genomic data that is harder for a general model to swallow. |
| How easily a giant could copy them | With a $500K note and 3 people, Atlas's approach could likely be rebuilt by any well-funded lab. | Insitro's mix of owned data and pharma ties makes copying possible but harder, not likely. |
| Pressure from rivals | Atlas faces heavier direct competitive pressure than Insitro, competing against established players like Insitro, Tempus AI, Unlearn.AI and Recursion that already hold the data deals it would need. | Insitro faces lighter direct competitive pressure, with its main threat being Isomorphic Labs, which raised $2.1B against Insitro's $400M Series C. |
| Financial footing | Atlas has raised just $500K on a convertible note and employs 3 people as of July 2026. | Insitro raised a $400M Series C in 2021, cut 22 percent of staff (63 people) in March 2025, and still employs about 230 people as of May 2025. |
| Overall defensibility | Atlas has almost no protection around its idea, given its $500K funding and 3-person team with no proprietary data assets. | Insitro's defensibility rests on years of proprietary genomic and cell data plus signed pharma deals with Lilly, Novartis and J&J. |
Questions people ask
- Is Atlas Discovery a good AI drug discovery startup?
- Atlas Discovery is very early, with only $500K raised and 3 employees. It has no named customers yet, while a company like Insitro already has multi-year deals with Lilly, Novartis and J&J.
- Which company has more funding, Atlas Discovery or Insitro?
- Insitro raised a $400M Series C in 2021, while Atlas Discovery has only raised $500K on a convertible note as of mid-2026. This gap shows up directly in headcount too, with Insitro around 230 employees versus Atlas's 3.
- Will AI replace Insitro or Atlas Discovery?
- Atlas Discovery is rated likely to be absorbed by broader AI tools, since its core prediction task is a common target for general models. Insitro is only rated partly exposed, because its work depends on proprietary genomic and cell data that is harder to substitute.
- Who is Insitro's biggest competitor?
- Insitro's main pressure comes from Isomorphic Labs, which raised $2.1B against Insitro's $400M and competes for the same pharma partners. Atlas Discovery is not currently a competitor to Insitro, since Atlas has no named customers of its own.